AI Index / Tempus AI, Inc.
Tempus AI, Inc. (TEM)
Tempus AI’s revenue comes from: 1) Genomics/diagnostic testing (oncology tissue xT/CDx, liquid xF, MRD xM, hereditary Ambry, rare/peds) — AI aids analysis but isn’t directly monetized; revenue is mainly test reimbursement. 2) Data & Services (Insights/data licensing to pharma, clinical trials/apps) — AI contributes directly, notably the AstraZeneca/Pathos foundation-model program (~$16M in Q2; Insights grew ~41%). AI is strategic, but direct AI dollars remain a minority versus testing.
Loading...
Obviously, we signed a very large deal to build a foundation model. So that's super exciting. That's under construction.
- Eric P. Lefkofsky
Similar Companies in the Swift AI Index
Quotes from tempus Executives About Artificial Intelligence and Generative AI
One of the things we would expect from this model, you're taking an enormous amount of data, right? We announced we have over 350 petabytes of connected clinical molecular data. This is massive data repository.
- Eric P. Lefkofsky
You're essentially running compute for months on a cluster of over 1,000 H200s, which are -- that's not a small amount of capacity.
- Eric P. Lefkofsky
And we expect if you kind of fast forward 5 or 10 years, my guess is targeted panels go away largely and people are just doing whole genome and whole transcriptome and layering in other markers like, for example, epigenomic methylation markers throughout those assays.
- Eric P. Lefkofsky
AI is going to again, create some significant disruption in the space.
- Eric P. Lefkofsky
We don't have a mechanism today as a system to reimburse for AI or algorithms, we have mechanisms to reimburse for kind of wet lab work.
- Eric P. Lefkofsky